CoChat
Sign Up
Cited by 248Cytokine Signaling Pathways and InteractionsInflammatory Biomarkers in Disease PrognosisImmune cells in cancer

The DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index, and 1 are not checked yet.

Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis

Open access
Lippitz, Bodo E., Harris, Robert A.·2016·OncoImmunology
DOI 10.1080/2162402x.2015.1093722PMC PMC4910721
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: In tumor patients, IL-6 appears to be one component of a consistent cancer-associated cytokine network resulting in both a systemic immune stimulation and a microenvironment of cancer-induced immune suppression that ultimately protects the cancer cells. IL-6 has been associated with prognosis in cancer patients, but so far a systemical analysis has not been carried out. METHODS: The present meta-analysis studies the relation between IL-6 serum levels and the prognosis of cancer patients in the available clinical literature of 100 articles published between 1993 and 2013 comprising 11,583 patients. RESULTS: The IL-6 serum level was described as significantly correlating with survival in 82/101 series comprising 85.6% of patients (9917/11,583) with 23 different cancer types. A total of 64 studies dichotomized patient cohorts according to various cut-off IL-6 serum levels: in 59/64 of these series corresponding to 94.5% of the reported patients (7694/8142) significant correlations between IL-6 serum level and survival were seen. The median survival of cancer patients had been determined above various cut-off levels of serum IL-6 in 24 dichotomized studies (26 cohorts). There was a highly significant inverse correlation between median survival of the cohorts with IL-6 serum level above cut-off (1272 patients) and their corresponding IL-6 cut-off values (Spearman R -0,48 p= < 0.001) following a linear regression when both parameters were log-transformed (p < 0.001). A significant correlation between increasing serum IL-6 and tumor stage or metastases was described in 39/44 studies and 91% of published patients (4221/4636) where clinical parameters had been specified. CONCLUSIONS: Closely associated with the patient's clinical condition and independent of the cancer histology, the increased IL-6 serum level uniformly appears to correlate with survival as paraneoplastic condition in later cancer stages independent of the cancer type. Modifications of this paraneoplastic immune reaction may offer new therapeutic options in cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2015.1093722

Cites

165 of 166 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Median survival of 1272 cancer patients with IL-6 serum levels above various chosen cut-off values in 24 dichotomized studies (26 cohorts). Both x and y parameters have been have log-transformed in the graph. Sample size was used to weigh the studies. The median survival at chosen cut-off points was inversely correlated to the minimum IL-6 serum level at this cut-off, both when sample size was used to weigh the studies (p < 0.001) and also when the cohorts were not weighted (p < 0.005). Numbers indicate series as listed in Table 2.
Figure 1. Median survival of 1272 cancer patients with IL-6 serum levels above various chosen cut-off values in 24 dichotomized studies (26 cohorts). Both x and y parameters have been have log-transformed in the graph. Sample size was used to weigh the studies. The median survival at chosen cut-off points was inversely correlated to the minimum IL-6 serum level at this cut-off, both when sample size was used to weigh the studies (p < 0.001) and also when the cohorts were not weighted (p < 0.005). Numbers indicate series as listed in Table 2.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 19

  1. Suzuki S, 2001, Int J Oncol, 18, 581
  2. De Vita F, 1998, Oncol Rep, 5, 649
  3. Bencosme A, 1996, Ann Clin Lab Sci, 26, 426
  4. 10.1097/01.shk.0000163802.46355.59 · DOI
  5. Svobodova S, 2011, Anticancer Res, 31, 373
  6. Ozdemir F, 2004, J Exp Clin Cancer Res, 23, 485
  7. Negus RP, 1997, Am J Pathol, 150, 1723
  8. Wu CW, 1996, Am J Gastroenterol, 91, 1417
  9. Chow KC, 2003, Oncol Rep, 10, 813
  10. Chung YC, 2006, Anticancer Res, 26, 3905
  11. Zhang GJ, 1999, Anticancer Res, 19, 1427
  12. Ujiie H, 2012, Anticancer Res, 32, 3251
  13. Katsumata N, 1996, Clin Cancer Res, 2, 553
  14. Wojcik E, 2010, Anticancer Res, 30, 1773
  15. Necula LG, 2012, J Gastrointestin Liver Dis, 21, 23
  16. Kallio JP, 2001, J Exp Clin Cancer Res, 20, 523
  17. Nakashima J, 2000, Clin Cancer Res, 6, 2702
  18. Mouawad R, 2006, Melanoma Res, 16, 335
  19. Kurzrock R, 1993, Cancer Res, 53, 2118

Cited by

Sorted by citations

See all 248

Related

See all

Metadata

Authors
Lippitz, B. E., & Harris, R. A.
Affiliations
Karolinska University Hospital (SE)
Corresponding author
Lippitz, Bodo E.
ORCID
Venue
OncoImmunology
Publisher
Informa UK Limited
Published
2016-05-03
Volume
5
Issue
5
Pages
e1093722
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
DOI
10.1080/2162402x.2015.1093722
PMC
PMC4910721
OpenAlex
W2365037335
Cited by
248
References
165
Citations by year
2026: 21 · 2025: 21 · 2024: 33 · 2023: 19 · 2022: 35 · 2021: 30 · 2020: 28 · 2019: 29 · 2018: 16 · 2017: 16
FWCI
2.05
Type
journal article
Language
en
Open access
Licence
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
interleukin-6, serum IL-6, cancer prognosis, cancer survival, cytokine network, tumor microenvironment, immunosuppression, tumor stage, metastasis, cancer immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review